A Phase II Study of Palbociclib (PD-0332991) in Combination With Ibrutinib in Patients With Previously Treated Mantle Cell Lymphoma
Phase of Trial: Phase II
Latest Information Update: 20 Nov 2019
Price : $35 *
At a glance
- Drugs Ibrutinib (Primary) ; Palbociclib (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- 19 Oct 2018 Status changed from not yet recruiting to recruiting.
- 31 Aug 2018 Planned End Date changed from 1 Aug 2022 to 1 Dec 2022.
- 31 Aug 2018 Planned primary completion date changed from 1 Feb 2022 to 1 Jun 2022.